
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
argenx
Market Cap: €43.1b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€702.00
7D
-1.4%
1Y
34.7%
Elia Group
Market Cap: €11.7b
Develops and operates as a transmission system operator in Belgium and Germany.
ELI
€106.70
7D
0.6%
1Y
16.0%
Groupe Bruxelles Lambert
Market Cap: €9.5b
Invests in a portfolio of industrial, consumer goods, and business service companies operating in various sectors in Belgium, other European countries, North America, and internationally.
GBLB
€78.45
7D
1.9%
1Y
15.5%
UCB
Market Cap: €46.8b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€243.20
7D
-2.2%
1Y
36.1%